The new report, "The Oncology Market Forecast to 2013," is a comprehensivestudy of more than 135 oncology drugs. The study takes a close look at themarket for five major oncology indications, including colorectal, leukemia,lung, prostate and breast cancer. It also includes detailed forecasts foreach drug, including forecasts for individual drug classes and top oncologydrug manufacturers(http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp).

The market outlook for breast cancer treatments is bright indeed. Roche'sand Genentech's blockbusters Avastin and Herceptin are currently undergoingclinical testing for cancer treatment. Meanwhile, several developmentaldrugs -- including Novartis' Gleevec -- are poised to take on the breastcancer market within the next couple of years. Gleevec is in Phase 3trials for advanced breast cancer, and is expected to be a boon forNovartis on the order of several billion in annual sales.

"The market for breast cancer treatment is certainly on an upwardtrajectory," said Eric Bolesh, lead author of the study. "Severalpromising therapies are in the pipeline, and the options for treatment areever-expanding -- which is good news for the industry and for patients."

The 420+ page study examines 17 monoclonal antibodies and more than 120other drugs, and provides the following market analysis:

--  Individual Drug Profiles - Drug profiles include information about    drugs' competitive, strategic and market growth positions.--  Oncology Indication Market Outlook - Detailed outlooks for the breast,    colorectal, lung and prostate cancer and leukemia markets.--  Company Profiles - Oncology breakdowns for companies that either have    established oncology franchises or exciting development pipelines for new    cancer compounds.